Literature DB >> 1866472

Increased plasma levels of neuropeptide Y-like immunoreactivity and catecholamines in severe hypertension remain after treatment to normotension in man.

L Edvinsson1, R Ekman, T Thulin.   

Abstract

Circulating levels of neuropeptide Y (NPY)-like immunoreactivity (-LI), adrenaline and noradrenaline (NA) were analysed in 17 patients admitted to the emergency ward due to severe hypertension; blood pressure mean 204/127 mmHg. The levels of NPY-LI and NA were significantly higher (P less than 0.001) in the hypertensives as compared to a normotensive control group. HPLC analysis revealed that the plasma contained besides NPY-LI also several NPY-LI fragments of low hydrophobicity. Following 2 to 3 weeks treatment the blood pressure had decreased to a mean of 150/89 mmHg. However, circulating levels of NPY-LI (P less than 0.001) and NA (P less than 0.01) were still significantly higher than in controls in spite of the marked reduction in blood pressure. Simultaneous measurements of adrenaline did not reveal any significant changes and these values did not differ compared with those in the normotensive subjects. The findings suggest that peripheral markers of the sympathetic system (NPY-LI and NA) in severe hypertension is not directly related to the blood pressure level.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1866472     DOI: 10.1016/0167-0115(91)90021-8

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  9 in total

1.  Plasma neuropeptide Y in impaired glucose tolerance.

Authors:  B Ahrén; H Larsson
Journal:  Acta Diabetol       Date:  1996-12       Impact factor: 4.280

2.  Attenuation of contractile responses to sympathetic co-transmitters in veins from subjects with essential hypertension.

Authors:  H Lind; D Erilnge; J Brunkwall; L Edvinsson
Journal:  Clin Auton Res       Date:  1997-04       Impact factor: 4.435

Review 3.  Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides.

Authors:  Julia Shanks; Neil Herring
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-09-04       Impact factor: 3.619

4.  Brain monoaminergic and neuropeptidergic variations in human aging.

Authors:  B Arranz; K Blennow; R Ekman; A Eriksson; J E Månsson; J Marcusson
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

5.  Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems.

Authors:  P Härle; R H Straub; R Wiest; A Mayer; J Schölmerich; F Atzeni; M Carrabba; M Cutolo; P Sarzi-Puttini
Journal:  Ann Rheum Dis       Date:  2005-06-07       Impact factor: 19.103

6.  Cloning and functional expression of cDNAs encoding human and rat pancreatic polypeptide receptors.

Authors:  H Yan; J Yang; J Marasco; K Yamaguchi; S Brenner; F Collins; W Karbon
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

7.  Sympathetic activation after two weeks of nifedipine treatment in primary Raynaud's patients and controls.

Authors:  J Leppert; H Nilsson; U Myrdal; L Edvinsson; T Hedner; I Ringqvist
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

8.  Alterations in perivascular dilatory neuropeptides (CGRP, SP, VIP) in the external jugular vein and in the cerebrospinal fluid following subarachnoid haemorrhage in man.

Authors:  R Juul; H Hara; S E Gisvold; A O Brubakk; T A Fredriksen; G Waldemar; J F Schmidt; R Ekman; L Edvinsson
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

Review 9.  Neuroimmune crosstalk in the pathophysiology of hypertension.

Authors:  Laura Calvillo; Mariela M Gironacci; Lia Crotti; Pier Luigi Meroni; Gianfranco Parati
Journal:  Nat Rev Cardiol       Date:  2019-08       Impact factor: 32.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.